ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryZugQuercis Pharma AG
Quercis Pharma AG Logo
Verified· 2 sources

Quercis Pharma AG

Summary

About the company

The core activity of Quercis Pharma AG is the development of pharmaceuticals, particularly the research and development of medications for the prevention of thrombosis and other diseases, such as cancer and neurological disorders. The company focuses on the development of Isoquercetin-based medications, such as Kinisoquin, and conducts clinical trials to test their efficacy and safety.

AI-generated
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Offering

Products & services

Industry:Pharmaceutical Industry
✓ Offered5
Development of investigational medicines
Development of investigational therapies based on Isoquercetin, including Kinisoquin™ and combinations with Zafirlukast, for multiple indications in oncology and beyond.
Clinical development in thrombosis and cancer
Clinical programs for the prevention and treatment of cancer-associated thrombosis, venous thromboembolism and hypercoagulability, including Phase 2 and Phase 3 studies.
Clinical development in sickle cell disease
Research and development program for sickle cell disease with Phase 2 and Phase 3 studies to reduce clotting and crises.
Clinical development in ALS, COPD and viral diseases
Further clinical programs in ALS, COPD and viral diseases focusing on inflammation, thrombosis, biomarkers and anti-thrombotic potential.
Expanded Access Program
Access to investigational medicines outside clinical trials for eligible patients with severe or life-threatening disease, assessed case by case by the treating physician.

Knowledge

No knowledge articles yet

Once Quercis Pharma AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Quercis Pharma AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Quercis Pharma AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Quercis Pharma AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Gubelstrasse 17
6300 Zug

At a glance

Legal form
Corporation
UID
CHE-449.717.928
Founded
2024 · 2 years
Last commercial register change
January 12, 2026
Employees
11 to 20

Similar companies

BA
Bioeq AG
Zug
BG
BioGntx Global R&D GmbH
Zug
A(
Amgen (Europe) GmbH
Rotkreuz
VA
Vesifact AG
Baar